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CLINICAL IMPLICATIONS OF
BRCA1 GENETIC TESTING FOR
ASHKENAZI-JEWISH WOMEN
Georgia L. Wiesner, MDt
THE COMPLEX ISSUES SURROUNDING genetic
testing for breast cancer susceptibility were recently highlighted
when a single mutation in a major breast cancer susceptibility
gene was found to exist with remarkably high frequency within
the Ashkenazi-Jewish population.' This genetic alteration,
185delAG, is easily identified by standard molecular tech-
niques and is one of over one hundred reported mutations in
the Breast Cancer 1 (BRCAl) gene.2 A major consequence of
this genetic discovery is that widespread testing and screening
is now possible for all women regardless of their previous risk
profile for developing breast cancer. Indeed, a commercial
testing company, Genetics and In-Vitro Fertilization (IVF)
Institute of Fairfax, Virginia, is currently marketing the
BRCA1, 185delAG test to general physicians and oncologists
for patients outside of scientific research protocols. As a result,
a debate about the merits of breast cancer susceptibility testing
gained national prominence.3
t Assistant Professor of Genetics and Medicine, Department of Genetics and Center for
Human Genetics, Case Western Reserve University and University Hospitals of Cleveland
1. See Jeffrey P. Struewing et al., The Carrier Frequency of the BRCAI J85delAG Muta-
tion is Approximately ) Percent in Ashkenazi Jewish Individuals, 11 NATURE GENMrCS 198, 198
(1995) (stating that the observed cancer frequency of 3RCAI in Ashkenazi individuals is several
times higher than the expected frequency of all BRCA1 mutations combined in the general
population).
2. See Francis S. Collins, BRCA1-Lots of Mutations, Lots of Dilemmas, 334 NEw ENG. J.
MED. 186, 186 (1996) (noting that the 185delAG is a frame-shift mutation at position 185 in exon
2 and involves a deletion of an adenine (A) and guanine (G) nucleotide); Donna Shattuck-Eidens
et al., A Collaborative Survey of 80 Mutations in the BRCAI Breast and Ovarian Cancer
Susceptibility Gene: Implications for Presymptomatic Testing and Screening, 273 JAMA 535,
537-39 (concluding that the high frequency of protein-terminating mutations found in the diverse
eighty mutation survey could lead to a relatively simple diagnostic test for BRCA1 mutations).
3. See Laurie Goodman, Breast Cancer Mutation Screening, 13 NATURE GENETICS 17, 17
(1996) (stating that although some researchers agree that women have a right to know about
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Offering BRCA1 genetic testing on a commercial basis is
controversial. Several national groups have strongly recom-
mended a cautious approach to incorporating genetic testing
into medical practice,4 and have published guidelines for
BRCA1 testing which propose that it be limited to high-risk
women under scientific protocols. This will ensure that the
benefits and limitations of testing are adequately understood
before it is offered to the general public. Clearly, genetic test-
ing for cancer susceptibility can have a profound and positive
impact on high-risk individuals and families.' However, pro-
viding unrestricted cancer susceptibility testing to the general
population raises several important questions about the risks
and benefits involved as well as how testing should be integrat-
ed into the health care for all Americans.6
The high frequency of the 185delAG mutation in
Ashkenazi-Jewish women also raises questions about the poten-
tial ethical and social impact on that community. How will
genetic disposition, many researchers feel that this information may cause the patient more harm
than good); Gina Kolata, Breaking Ranks: Lab Offers Test To Assess Risk of Breast Cancer, N.Y.
TIMES, Apr. 1, 1996, at Al (stating that a private commercial institute that was not part of any
agreement to hold back the breast cancer test decided to offer the test despite the still-remaining
unanswered questions); Open Letter from the Genetic & IVF Institute (Apr. 1996) (on file with
author) (announcing the Institute's Plan to begin offering 185delAG BRCA1 mutation testing).
4. See generally American Society of Clinical Oncology, Statement of the American
Society of Clinical Oncology: Genetic Testing for Cancer Susceptibility, 14 J. CLINICAL
ONCOLOGY 1730 (1996) (setting forth the American Society of Clinical Oncology's position on
genetic testing and the ethical and psychological impact of these tests). See also National
Advisory Council for Human Genome Research, Statement on Use of DNA Testing for
Presymptomatic Identification of Cancer Risk, 271 JAMA 785, 785 (1994) [hereinafter National
Advisory Council] (proposing a series of questions that must be addressed before incorporating
genetic testing into medical practice); American Society of Human Genetics, Statement of the
American Society of Human Genetics on Genetic Testing for Breast and Ovarian Cancer
Predisposition, 55 AM. J. HUM. GENETICS i, i (1994) [hereinafter ASHG] (recommending that
testing should initially be offered and performed on an investigational basis by appropriately
trained health care professionals who have a therapeutic relationship with the patient and are fully
aware of the genetic, clinical, and psychological implication of testing, as well as the limitations
of testing).
5. See Barbara B. Biesecker et al., Genetic Counseling for Families with Inherited
Susceptibility to Breast and Ovarian Cancer, 269 JAMA 1970, 1971 (1993) (reporting the
dramatic impact which early detection of breast cancer susceptibility has had on women who were
tested for the BRCA1 mutation).
6. See Goodman, supra note 3, at 17 (stating that many researchers believe that the
information obtained from genetic screening may be harmful given the uncertain consequences of
a positive test); Judy E. Garber & Deborah Schrag, Testing for Inherited Cancer Susceptibility,
275 JAMA 1928, 1928-29 (1996) (discussing the need for physicians to become aware of
psychological, behavioral, and logistical impacts of genetic testing).
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members of the Jewish community utilize this genetic informa-
tion? Is this genetic mutation found solely in the Jewish popu-
lation? Should genetic testing be available to all persons who
want to be tested? Will genetic testing be required by employ-
ers and third-party payers for health insurance? Who will have
access to the test results? What are the limitations of genetic
tests? With what accuracy does BRCA1 testing predict the
occurrence of breast cancer? This Article will provide a frame-
work for understanding the impact of genetic testing for breast
cancer risk in Ashkenazi-Jewish women by reviewing the sci-
entific basis for cancer susceptibility testing as well as essential
concepts of inheritance and the genetics of breast cancer.
I. A TALE OF TWO WOMEN: THE TESTING
DILEMMA
In order to appreciate the potential impact of genetic test-
ing for a community or society, we must first understand the
clinical process of susceptibility testing for cancer. The follow-
ing two clinical histories from the Center for Human Genetics
at University Hospitals of Cleveland illustrate the complex
issues facing women who are considering predictive and diag-
nostic genetic testing for BRCA1' These case studies also
demonstrate that the decision to have testing must be made
carefully. Each woman deliberated the benefits and risks of
testing over an extended period of time before reaching a final
decision.
A. Case One
BET was a forty-two-year-old Jewish woman who was
referred by her surgeon to the Cancer Genetics Clinic for con-
sultation prior to prophylactic mastectomy. She had questions
about her risk for developing breast cancer and whether she
7. A combined program in Cancer Genetics was established in October, 1994 in the
Center for Human Genetics and the Department of Genetics in Case Western Reserve University
and University Hospitals of Cleveland. Specialized clinics to evaluated patients for familial breast
and colon cancer were begun in March, 1995. The cases provided here have been slightly
modified to protect the identity of the patients and their families. The patient abbreviations are
fictitious as are minor details about the family structure as shown in the pedigrees in Figure 1 and
2.
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should consider removal of her normal breast tissue as a pre-
ventative measure for breast cancer. Her older sister, who is
now fifty-two years old, had developed breast cancer twelve
years before at the age of forty-one (Figure 1). In addition, her
mother and maternal grandmother had both developed ovarian
cancer late in life and her father had died of colon cancer. A
distant cousin on her mother's side had also developed ovarian
cancer. She was not concerned about her risk for ovarian can-
cer since her uterus and ovaries had been surgically removed
because of an unrelated medical condition. In addition to her
own health-related issues, she wondered what could and should
be done to predict cancer in her fourteen-year-old daughter.
Figure 1.
Center for Human Genetics
CGC- Family 041
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Male or female, no cancer
Figure 1
Pedigree "MCT/BET" Case
Initial review of her family medical tree showed that while
several members had developed cancer, it was not the "classic"
scenario for the hereditary breast ovarian syndrome. This deter-
mination was made despite the small size of BET's family and
her lack of detailed information on distant relatives. However,
the fact that her sister developed breast cancer prior to meno-
pause coupled with the fact that their mother had ovarian can-
cer concerned the genetics team that met with BET. After a
8. Genetic evaluation and counseling sessions consist of a support person (if the patient
[Vol. 7:3
CLINICAL IMPLICATIONS
complete discussion of the risks and benefits of testing, she
was advised that predictive genetic testing for the BRCA1 gene
was possible for her. Most importantly, the counselor felt that
BRCA1 testing could assist her in making her decision about
prophylactic breast surgery. If she did carry a BRCAI genetic
alteration, then BET felt that she would have a prophylactic
mastectomy in order to markedly reduce her risk of breast
cancer. In contrast, if she did not carry a BRCA1 genetic alter-
ation, then her risk for developing breast cancer would be
much smaller, comparable to the population risk for all women,
and she felt that she would avoid breast surgery.
The process of predictive testing was discussed with BET.
The first step in the process was to analyze the pedigree by
reviewing the surgical and pathology reports on all family
members with cancer. Secondly, it was explained that for pre-
dictive testing to be useful for BET, the genetic test for the
BRCA1 gene should first be performed on an individual in the
family who was suspected of developing cancer because of an
inherited susceptibility. This step is necessary because it con-
firms that a genetic mutation is identifiable in the patient's
family. In BET's case, it was suggested that the BRCA1 test
should be performed on her older sister. If her sister's genetic
test was positive for a BRCA1 mutation, then BET could
choose to have predictive testing.
After her initial visit, BET was faced with unanticipated
decisions. While she understood that genetic testing would help
her with her decision for prophylactic surgery, she was not
prepared to approach other family members with what she felt
was a private decision. In particular, she was concerned about
her sister's well-being. She was hesitant to discuss genetic
testing with her sister because BET did not want to cause her
additional emotional distress. Thus, BET agreed to supply
medical records on her mother's cancer diagnosis while she
considered her choices.
Approximately five months after her initial visit, BET
returned to the clinic with her sister, MCT. BET and MCT
wishes) a genetic counselor, and a medical geneticist. Both genetic counselor and physician have
expertise in cancer genetics. Review of family information and final recommendations are done in
conjunction with the patient's primary physician, oncologist, or surgeon.
1997]
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were told the limitations of testing, as well as the actual testing
procedure prior to collecting their blood samples. The BRCA1
185delAG mutation was also specifically discussed because of
their Ashkenazi-Jewish heritage. They were aware that in order
for BET to have predictive testing, MCT would undergo diag-
nostic genetic testing with the intention of sharing the results
with BET. The test was performed after receiving each sister's
informed consent.
BET and MCT both returned to the clinic to learn their
results approximately one month later. MCT, the sister who
had developed breast cancer when she was forty-one years old,
had the BRCA1 mutation, 185delAG. This mutation is com-
monly found in Ashkenazi-Jewish women. BET also learned
that she shared the same 185delAG mutation with her sister.
The implications of the gene test were discussed with each
sister and plans for cancer screening and surgery were made.
For BET, the process of genetic testing had taken approximate-
ly six months and required prolonged deliberation of her per-
sonal beliefs. While saddened by the result of her genetic test,
she was determined to use the information as a preventative
measure.
B. Case Two
JB is a forty-seven-year-old Jewish woman who developed
cancer of the right breast when she was forty-six years old.
She was referred to the Cancer Genetics Clinic for a discussion
about prophylactic surgery for her left breast. Her family tree
has numerous members with cancer including breast, ovarian,
and stomach cancers. Her mother had bilateral breast cancer at
age forty-six and her maternal grandmother had ovarian cancer
in her fifties. The family tree is illustrated in Figure 2. In dis-
cussing her concerns with the genetic counselor and medical
geneticist, JB was most concerned about her chances of devel-
oping a second cancer in her left breast. Her family pedigree
was consistent with an inherited cancer family syndrome, in-
cluding the hereditary breast-ovarian syndrome. All of these
factors made BRCA1 testing possible.
[Vol. 7:3
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Pedigree "JB" Case
Counseling involved a review of JB's family pedigree and
a discussion of the risk of developing additional cancers in
carriers of BRCA1 mutations, such as ovarian and contralateral
breast cancer. The potential risk for developing ovarian cancer
was surprising to JB, who was initially concerned about devel-
oping bilateral breast cancer as her mother had. In considering
testing, JB also needed to consider the technical limitations of
genetic testing. Since her personal and family history was sug-
gestive of an inherited cancer family syndrome, it was most
likely that her previous breast cancer was caused by an inher-
ited susceptibility gene.
Before continuing with JB's case study, it is important to
note that there are two separate factors that can decrease the
chance of identifying a specific mutation in a cancer predispo-
sition gene. First, the BRCA1 test is approximately ninety
percent sensitive.9 Therefore the test could possibly yield a
9. Sensitivity is defined as the proportion of people with the disease who do have a
19971
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negative result because of technological complexities of the
laboratory performance. Second, there are several genes that
can cause familial breast cancer (see Table 1) and not all genes
currently can be tested.
With this in mind, one possible explanation for the clus-
ters of cancer in her family could be a BRCA1 mutation, how-
ever, it also could be due to other breast cancer susceptibility
genes such as those that cause the Hereditary Non-polyposis
Colorectal Cancer syndrome or other unidentified genes. In
addition, consideration had to be given to a chance occurrence
of a cluster of common cancers occurring in her family.
JB was also faced with decisions that she had not antic-
ipated prior to meeting with the genetics team. She was sur-
prised that she had an elevated risk for ovarian cancer and,
furthermore, that BRCA1 testing was not one hundred percent
accurate. In addition, JB was concerned about insurance dis-
crimination and did not want the genetic testing to put her
health insurance coverage at risk. Therefore, she declined to
have the test after careful deliberation over a three-month peri-
od of time. However, because of her elevated risk for develop-
ing ovarian cancer, she was receptive to having a prophylactic
removal of her ovaries. JB explained that she based her deci-
sion on the analysis of her family tree during her clinic visit.
At that time she had been told that she probably carried a
cancer susceptibility gene, since she had developed breast can-
cer at an early age. Therefore, JB felt that the genetic test
result would not clarify her risk for other cancers. Rather, she
feared that it might impose a larger burden by potentially re-
sulting in the loss of her health insurance coverage.
II. THE AGE OF GENETIC DISCOVERY
A quiet revolution has taken place in our understanding of
the genetic mechanism of disease over the last forty-three years
since James Watson's and Francis Crick's discovery of the
positive test and measures the accuracy of a specific laboratory test. See MARCUS HERMANSEN,
BIoSTATISTICS: SOME BASIC CONCEPTS 172-73 (1990) (defining the relationship between
predictive value, sensitivity, and specificity). Thus, for BRCAI families, testing would yield a
true positive result 90% of the time. Id.
[Vol. 7:3
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double helical structure of DNA."0 Indeed, over the last 130
years, medical science has moved from the notion of units of
heredity, as proposed by Gregor Mendel in 1865," to the first
description of a genetic disease, alkaptonuria, in 1909.12
Genes were physically mapped to chromosomes in 1910,"3
and DNA was discovered as the molecule of inheritance in
1944." When the ambitious Human Genome Project was ini-
tiated in 1990, mapping and sequencing the entire human ge-
nome was a dream. 5 Now, in 1996, the physical mapping pro-
ject is nearly complete, 6 and genetic scientists are focused on
locating each of the estimated 100,000 genes located on the
twenty-three human chromosome pairs. 7
In a relatively short time span, this information has enor-
mously impacted our understanding of the biochemical and
molecular basis of disease and has led to the development of
new paradigms for medical science. Clinical laboratory test-
ing has focused on the diagnosis of disease after a patient
develops characteristic signs and symptoms of illness. Health
care delivery now includes identifying high-risk patients, prior
to the development of symptoms, by searching for specific
genetic alterations known to cause diseases. 9 Prior knowledge
of potential illness can be advantageous because specific health
10. See GUNTHER S. STENT & RICHARD CALENDAR, MOLECULAR GENETICS: AN
INTRODUCrORY NARRATIVE 202-08 (1978).
11. See id at l-7.
12. See HARRY HARRIS, THE PRINCIPLES OF HUMAN BIOCHEMICAL GENETICs 187 (A.
Neuberger & E.L. Tahim ed., 2nd ed., 1975) (discussing Garrad's concept of pathogenesis and the
genetic disorder alkaptonuria).
13. See STENT & CALENDAR, supra note 10, at 17-21 (discussing T. H. Morgan's
experiments which establish a genetic map of the drosophila chromosomes).
14. See id. at 23 (noting Oswald Avery's discovery that genes are embodied in DNA).
15. See James D. Watson, The Human Genome Project: Past, Present, and Future, 248
ScIENCE 44, 47 (1990) (discussing some of the scientific strategy and methodology needed to be
worked out to achieve the goals of the 1990 plan).
16. See Francis Collins & David Galas, New Five-Year Plan for the U.S. Human Genome
Project, 262 SCIENCE 43, 43 (stating that in 1993, progress toward achieving the first set of goals
for the genome project was on schedule, and in some instances, even ahead of schedule).
17. See MARGARET W. THOMPSON Er AL., GENETics iN MEDICINE 31 (1991) (discussing
the organization of the human genome).
18. See Victor A. McKusick, The New Genetics and Clinical Medicine: A Summing Up,
Hosp. PRAC., July 15, 1988, at 177, 181 (summarizing some of the more striking aspects of the
biochemical and molecular basis of disease and the remarkable possibilities this approach has
opened up).
19. See Arno G. Motulsky, Predictive Genetic Diagnosis, 55 AM. J. HUM. GENETICS 603,
603 (1994) (discussing various applications of genetic screening prior to the onset of the disease).
19971
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screening measures can be instituted to minimize morbidity and
mortality." While predictive or presymptomatic testing can
currently identify only a small fraction of human disorders,2'
the direct incorporation of genetic discoveries from basic sci-
ence into the practice of medicine is at the forefront of a new
medical model of health care.
III. GENETIC BASIS OF CANCER
The advances in molecular biology and human genetics
over the last two decades have led to a greater appreciation of
the underlying cellular and genetic mechanisms of the neoplas-
tic process. The current model of carcinogenesis is that both
inherited and sporadic cancers are due to genetic alterations in
the nucleus of a single cell.22 However, the development of a
tumor is not an instantaneous event. Rather, a cell becomes
cancerous after a series of genetic and cellular alterations that
disable the normal mechanisms that control how the cell grows
and divides.' In this view, a neoplastic tumor can be thought
of as a disorder of cell regulation which leads to an expansion
of the initial malignant cell with numerous clonal malignant
daughter cells that eventually metastasizes to other tissue sites.
Except in extremely rare situations, the presumption is that
no single genetic alteration is adequate to produce malignant
transformation and tumor development. The accumulation of
several mutations in key regulatory genes, however, results in
loss of control over the normal cell cycle checkpoints and other
regulatory steps.24 Thus, there is an increase in abnormal cel-
20. See Biesecker etal., supra note 5, at 1971.
21. See generally Howard Markel, The Stigma of Disease: Implications of Genetic
Screening, 93 Am. J. MED. 209 (1992) (discussing the concept of "quarantine mentality" and the
desire of society to separate itself from those labeled "ill" within the context of new advances in
genetic technology). See also Goodman, supra note 3, at 17 (discussing ethical issues raised by
genetic screening).
22. See J. Michael Bishop, Molecular Themes in Oncogenesis, 64 CELL 235, 238 (1991)
[hereinafter Bishop, Molecular Themes] (discussing the inheritance of cancer); J. Michael Bishop,
The Molecular Genetics of Cancer, 235 SCIENCE 305, 305, 310 (1987) (reviewing the means by
which proto-oncogenes have been identified and the evidence that damage to these genes may be
involved in the genesis of cancer).
23. See Andrew W. Murray, Creative Blocks: Cell-Cycle Checkpoints and Feedback Con-
trols, 359 NATuRE 599, 603-04 (1992) (concluding that failures in feedback control mechanisms,
which regulate the cell cycle, can contribute to the generation of cancer).
24. See id. See also Bert Vogelstein et al., Genetic Alterations During Colorectal-Tumor
[Vol. 7:3
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lular proliferation with the development of a malignant tumor.
Instability of the genetic material in the cell nucleus is a hall-
mark of neoplasia and is exhibited by cytogenetic and molecu-
lar abnormalities in many tumor types. As the tumor pro-
gresses, there are increasing non-random alterations in several
regions of the genome.
An important conceptual model which explains the occur-
rence of inherited and sporadic cases of cancer was first pro-
posed by Alfred G. Knudson in 1971.26 Using familial and
isolated cases of retinoblastoma, a rare childhood eye tumor, he
suggested that a somatic mutation occurs in each copy of a
putative gene before a tumor can form in the immature retina
cell, or retinoblast. Since each cell carries two copies of each
gene, such mutations occur as a rare event in the life of a cell
and are seen as a sporadic, rare case of retinoblastoma. How-
ever, if a mutation is inherited from a parent with retino-
blastoma, the child carries an altered germline susceptibility
gene. In other words, the specific mutation is found in the ge-
netic material in all cells of the body. In this case, one addi-
tional somatic mutation in the corresponding allele27 of a
single cell initiates the neoplastic process. This model was
shown to be accurate in subsequent investigations showing cy-
togenetic abnormalities in retinoblastoma tumor cells, the iden-
tification of the retinoblastoma gene on human chromosome
13, and family studies of retinoblastoma.2
Development, 319 NEW ENG. J. MED. 525, 525 (1988) (finding that the colorectal-tumor
developmental model often involves the mutational activation of an oncogene coupled with the
loss of several genes that normally suppress tumorigenesis).
25. See Russell F. Jacoby et al., Genetic Instability Associated with Adenoma to Carcinoma
Progression in Hereditary Nonpolyposis Colon Cancer, 109 GASTROENTEROLOGY, 73, 73, 81
(1995) (correlating genetic instability to the pathogenesis of carcinoma in hereditary nonpolyposis
colon cancer); Vogelstein et al., supra note 24, at 529-31. See also Floyd Thompson et al., Clonal
Chromosome Abnormalities in Human Breast Carcinomas, 7 GENES, CHROMOSOMES, CANCER
185, 191-93 (1993) (illustrating the frequent finding of clonal chromosome abnormalities in
human primary breast cancers).
26. Alfred G. Knudson, Jr., Mutation and Cancer: Statistical Study of Retinoblastoma, 68
PROC. NAT'L ACAD. Sci. 820,820 (1971) (suggesting the possibility that tumors are distributed in
accord with a Poisson distribution).
27. See THOMPSON ET AL., supra note 17, at 373 (comparing Mendelian and sporadic
forms of cancer). An allele is one of a pair of genes located at a specific chromosomal site or
locus. See id. at 53.
28. See W.K. Cavenee et al., Expression ofRecessive Alleles by Chromosomal Mechanisms
in Retinoblastoma, 305 NATURE 779, 780 (1983) (confirming the two-step mechanism of
tumorigenesis whereby a subsequent event in a predisposed retinal cell results in homozygosity
1997]
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The Knudson hypothesis was a crucial step in our under-
standing of inherited cancers and has provided a framework for
cancer research and discovery. Other tumor types, such as
colon cancer and breast cancer, follow the more complex mod-
el of multi-stage carcinogenesis where mutations in several
regulatory genes must occur before malignant transformation of
the cell.29 In addition, environmental factors influence the de-
velopment of cancer and there may be gene-environmental
factors that cause transformation or progression of cancer."
It must be remembered that for the majority of individuals,
cancer is a sporadic event, occurring in the absence of an in-
herited predisposition to malignancy. However, a small propor-
tion of adults and children carry an inherited, germline muta-
tion in a cancer predisposition gene.3 This genetic alteration
places them at an increased risk of developing cancer over
their lifetimes. Such genetic susceptibility does not mean that
all mutation carriers will develop cancer. In fact, the causative
genes for most family cancer syndromes, including breast
cancer, are not fully penetrant.32 The expression of the cancer,
therefore, depends upon a complex chain of events where mu-
tations in a major predisposition gene interact with mutations
in other modifier genes and with other environmental factors.
The explosion of information about the molecular basis of
human disease and genetic susceptibility has been most pro-
nounced in the study of breast cancer. Several genes causing
breast cancer have been recently located and cloned.33 Fur-
for the mutant allele). See generally Veronique Blanquet et al., Spectrum of Germline Mutations
in the RBI Gene: A Study of 232 Patients with Hereditary and Non-Hereditary Retinoblastoma, 4
HuM. MOLECULAR GENETICS 383 (1995) (reporting novel germline mutations in the
retinoblastoma gene of hereditary and non-hereditary RB patients).
29. See Vogelstein et al., supra note 24, at 531.
30. See Bishop, Molecular Themes, supra note 22, at 237 (noting that many of the
experimentally documented carcinogens may act indirectly as mutagens by stimulating cellular
proliferation that, in turn, increases the probability of converting endogenous DNA damage into
mutations); Mark H. Skolnick & Lisa A. Cannon-Albright, Genetic Predisposition to Breast
Cancer, 70 CANCER 1747, 1749 (1992) (diagramming a model of how environmental factors
impact inherited cancer predispositions).
31. SeeStruewingetal.,supranote 1,at 198.
32. Penetrance is the proportion of gene carriers that express, or show signs or symptoms,
of the genetic trait in question. See THOMPSON ET AL., supra note 17, at 83. For family cancer
syndromes, a penetrance level of .90 indicates that 90% of individuals known to carry the
abnormal gene will develop cancer.
33. See generally Kinneret Savitsky et al., A Single Ataxia-Telangiectasia Gene with A
[Vol. 7:3
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thermore, it is estimated that approximately five to ten percent
of all cancers are caused by an inherited susceptibility gene. 4
This has had a tremendous impact on breast cancer prevention
by potentially identifying women at risk for breast cancer prior
to the development of disease. However, there are several
unanswered questions about how to appropriately integrate
cancer risk assessment into clinical health care.
IV. THE GENETICS OF BREAST CANCER
Breast cancer is a substantial national health concern be-
cause it is the most common cancer in American women today.
Approximately 180,000 women are diagnosed with breast can-
cer each year, and another 46,000 women will die of the dis-
ease." Current estimates suggest that nearly one out of eight
Product Similar to PI-3 Kinase, 268 SCIENCE 1749, 1749 (1995) (identifying the ATM gene
which is believed to be involved in the autosomal recessive disorder ataxia-telangiectasia); Ethan
Lange et al., Localization of an Ataxia-Telangiectasia Gene to an -500-kb Interval on
Chromosome 11q23.1: Linkage Analysis of 176 Families by an International Consortium, 57 AM.
J. HUM. GENETCS 112, 112-15 (1995) (localizing the gene for Ataxia-Telangiectasia); Fredrick s.
Leach et al., Mutations of a mutS Homolog in Hereditary Nonpolyposis Colorectal Cancer, 75
CELL 1215, 1215 (1993) (discussing the mutS homolog in HNPCC); Richard Fishel et al., The
Human Mutator Gene Homolog MSH2 and its Association with Hereditary Nonpolyposis Colon
Cancer, 75 CELL 1027 (1993) (explaining that gene MSH2 has been mapped and found to be
associated with hereditary nonpolyposis colon cancer); Jean Feunteun et al., A Breast Ovarian
Cancer Susceptibility Gene Maps to Chromosome 17q21, 52 AM. J. HUM. GENETICs 736 (1993)
(confirming the location of a dominant gene that confers susceptibility to breast and ovarian
cancer); Yushio Mild et al., A Strong Candidate for the Breast and Ovarian Cancer Susceptibility
Gene BRCA1, 266 SCIENCE 66 (1994) (identifying a strong candidate for the BRCAl gene);
Elizabeth Culotta & Daniel E. Koshland, Jr., P53 Sweeps Through Cancer Research, 262 SCIENCE
1958, 1959 (1993) (noting that in 1993 several teams of scientists cloned a gene that carries out at
least a part of p53's tumor suppression activity); Nicholas C. Nicolaides et al., Mutations of Two
PMS Homologues in Hereditary Nonpolyposis Colon Cancer, 371 NATURE 75, 75 (1994)
(reporting the nucleotide sequence, chromosome localization, and mutational analysis of hPMS1
and hPMS2, which were found to be mutated in the germline of HNPCC patients); C. Eric
Bronner et al., Mutation in the DNA Mismatch Repair Gene Homologue hMLHI is Associated
with Hereditary Non-polyposis Colon Cancer, 368 NATURE 258, 258 (1994) (proposing that
hMLHI is the HNPCC gene located on 3p because of the similarity of the hMLH1 gene product
to yeast DNA mismatch repair protein, MLH1).
34. See Mary-Claire King et al., Inherited Breast and Ovarian Cancer: What are the Risks?
What are the Choices?, 269 JAMA 1975, 1975 (1993) (stating that the goal of identifying genes
responsible for breast cancer is to learn biological features of the disease that can be studied for
the development of preventive strategies); Ruth Ottman et al., Familial Breast Cancer in a
Population-Based Series, 123 AM. J. EPIDEMIOLOGY 15, 15 (1986); Mary-Claire King, Breast
Cancer Genes: How Many, Where and Who are They?, 2 NATURE GENETIcS 89, 89 (1992)
(stating that it is important to determine which compounds are most effective against each tumor
genotype).
35. See Craig Henderson, Breast Cancer, in AMERICAN CANCER SOCIETY TEXTBOOK OF
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to ten women will develop breast cancer at some point in their
lives.36 Breast cancer is etiologically and genetically heteroge-
neous.37 For most women, a combination of family history
and reproductive factors, such as age at menarche, age at first
birth, and parity, are important for the development of breast
cancer.38 Large epidemiologic studies have consistently dem-
onstrated that family history is an independent risk factor for
the development of breast and other cancers. 39 Approximately
twenty to thirty percent of all breast cancers occur in women
with a family history of the disease in a close female rela-
tive.' For a woman with a mother, sister, or daughter with
breast cancer, the odds of developing breast cancer are mildly
elevated, two to three times over the general population risk."
However, this risk can be as high as nine to ten times the
population risk when more than one relative is affected, or if
the cancer developed at a young age in the family member.42
There are several rare family cancer syndromes that have
CLINICAL ONCOLOGY 198, 198-99 (Gerald P. Murphy et al. eds., 1995).
36. See Graham A. Colditz, Epidemiology of Breast Cancer: Findings from the Nurses'
Health Study, 71 CANCER 1480, 1480 (1993) (noting that the average years of life lost by those
with breast cancer (twenty years) is higher for American women than the average of all cancers
combined (sixteen years)); Kathy A. Fackelmann, Refiguring The Odds: What's a Woman's Real
Chance of Suffering Breast Cancer?, 144 SC. NEws 76, 76 (1993) (translating statistical risks of
breast cancer in women to reflect age and to compare with other common health problems).
37. See generally King, supra note 34, at 89-90.
38. See generally King et al., supra note 34, at 1975.
39. See James SL John et al., Cancer Risk in Relatives of Patients with Common Colorectal
Cancer, 118 ANNALS INTERNAL MED. 785, 788 (1993) (examining risk for colorectal cancer in
first-degree relatives of patients with common colorectal cancer); Gary D. Steinberg et al., Family
History and the Risk of Prostate Cancer, 17 PROSTATE 337, 343 (1990) (relating the risk of
developing prostate cancer with a family history of the disease); Lisa A. Cannon-Albright et al.,
Familiality of Cancer in Utah, 54 CANCER RES. 2378, 2382-84 (1994) (discussing the familial
component of both rare and common cancers in Utah).
40. See Skolnick & Cannon-Albright, supra note 30, at 1751.
41. See Ottman et al., supra note 34, at 18-20.
42. See Elizabeth B. Claus et al., Genetic Analysis of Breast Cancer in the Cancer and
Steroid Hormone Study, 48 AM. J. OF HUM. GENETICS 232, 236-39 (1991) (investigating the
ability of a number of possible genetic models to fit the observed patterns of transmission of
breast cancer in a population-based, case-controlled study); Elizabeth B. Claus et al., Autosomal
Dominant Inheritance of Early-Onset Breast Cancer: Implications for Risk Prediction, 73
CANCER 643,644-46 (1994) (illustrating the importance of appropriate screening for patients with
a family history of breast cancer); Henry T. Lynch et al., Familial Risk and Cancer Control, 236
JAMA 582, 583 (1976) (demonstrating a significant correlation between family and personal
history of cancer in a 4,515 patient study); Ann Grossbart Schwartz et al., Risk of Breast Cancer
to Relatives of Young Breast Cancer Patients, 75 J. NAT'L CANCER INST. 665, 667 (1985).
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an associated risk for breast cancer.43 Family cancer syn-
dromes are recognized by a detailed analysis of the family tree
and are characterized by the occurrence of cancers at an unusu-
ally early age. In addition, families can have many members
affected with cancer over many generations. Multiplex families
can have a variety of both common and rare tumor types, such
as breast, colon, ovarian, and prostate cancer." A complete
review of the family medical tree is important to characterize
the type of familial breast cancer. Only then can the appropri-
ate testing and cancer screening be performed.45 The major
forms of familial breast cancer include site specific breast
cancer, the hereditary breast-ovarian syndrome, Li-Fraumeni
syndrome, the Hereditary Non-Polyposis Colon Cancer syn-
drome, and breast cancer in relatives of patients with the atax-
ia-telangiectasia syndrome.' Many genes responsible for these
disorders have been identified and are listed in Table 1.
The Hereditary Non-Polyposis Colon Cancer, or Lynch
syndrome, is a family cancer syndrome where family members
develop colon, rectal, and other cancers.47 Like other familial
syndromes, the types of cancers in the family are variable so
that relatives are also seen with uterine, ovarian, gastric, and
breast cancers. While the chance of developing colon cancer
approaches eighty to ninety percent over a patient's lifetime,
the risk for developing breast cancer in these families is only
mildly elevated over that of the general population.'
43. D.G.R. Evans etal., Familial Breast Cancer, 30 BRIT. MED. J. 183, 184-85 (1994).
44. Lynch et al., supra note 42, at 58 (listing several types of mendelian-transmitted can-
cers); Cannon-Albright et al., supra note 39, at 2379-80.
45. See Lisa Sclafani, Management of the High-Risk Patient, 7 SEMINARS SURGICAL
ONCOLOGY 261, 261-266 (1991); John J. Mulvilhill, Genetic Counseling of the Cancer Patient, in
2 CANCER: PRINCIPLES AND PRACrICE OF ONCOLOGY 2529, 2530-31 (Vincent T. DeVita, Jr. et
al. eds., 1993) (describing a paradigm for genetic counseling of cancer patients).
46. See King et al., supra note 34, at 1975; Michael Swift et al., Incidence of Cancer in 161
Families Affected by Ataxia-Telangiectasia, 325 NEW ENG. J. MED. 1831, 1831 (1991)
[hereinafter Incidence of Cancer] (demonstrating that persons heterozygous for the ataxia-
telangiectasia gene have an excess of cancer, particularly breast cancer in women).
47. See Henry T. Lynch et al., Hereditary Nonpolyposis Colorectal Cancer (Lynch Syn-
dromes I and II), 56 CANCER 939, 939 (1985) (describing biomarker findings that show variable
association with the cancer-prone genotype in patients with hereditary non-polyposis colorectal
cancer).
48. See Piero Benatti et al., Tumor Spectrum in Hereditary Non-Polyposis Colorectal
Cancer (HNPCC) and in Families with "Suspected HNPCC": A Population-Based Study in
Northern Italy, 54 INT'L J. CANCER 371, 374 (1993) (describing the tumor spectrum and most
relevant clinical features of twenty-eight kindreds of HNPCC and of sixty-one "suspected"
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A link between breast cancer and a rare genetic childhood
disease was first described in 1987.'9 This study focused on
ataxia-telangiectasia, a devastating autosomal recessive
neurodegenerative disease that strikes young children.0 Char-
acteristic findings in homozygous patients include progressive
cerebellar ataxia, loss of developmental milestones, vascular
abnormalities of the skin, and a striking increase in risk of
cancer. Blood relatives also have an increased risk of devel-
oping cancer. Although the study was criticized for the statisti-
cal methods employed for analysis,5 Michael Swift, et al.
reported that female relatives have a risk5 2 for breast cancer of
5.1 times over the general population. 3
Other rare family syndromes are associated with breast
cancer. Bilateral breast cancer in young women is also seen in
families with the Li-Fraumeni syndrome.54 This family cancer
syndrome is characterized by a striking cluster of early onset
breast cancer plus other tumors including osteosarcoma, leuke-
mia, brain tumors, and adrenal cortical tumors." Cowden syn-
drome, which is an autosomal dominant disorder of thyroid
dysfunction, thyroid cancer, and intestinal polyposis is also
associated with an elevated risk of breast cancer.56
HNPCC).
49. See Michael Swift et al., Breast and Other Cancers in Families with Ataxia-Tel-
angiectasia, 316 NEw ENG. J. MED. 1289, 1289 (1987) (demonstrating that breast cancer in
women is clearly associated with heterozygosity for ataxia-telangiectasia).
50. See Johns Hopkins University, Online Mendelian Inheritance in Man, (last modified
Aug. 22, 1996) <http://www3.ncbi.nm.gov/omim> [hereinafter Mendelian Inheritance in Man].
51. See Lewis H. Kuller & Baruch Modan, Risk of Breast Cancer in Ataxia-Telangiectasia,
326 NEw ENG. J. MED. 1357, 1357 (1992) (raising methodologic problems presented by the
control group chosen by Swift et al.).
52. Relative risk is the risk of developing a disease if you have an exposure or specific
factor compared with the risk of developing a disease if the exposure or specific factor is not
present. See HERMANSEN, supra note 9, at 164-65 (describing how to approach correlations using
nominal data as compared with correlations using continuous and ordinal data). As such, a relative
risk of 5.1 indicates a five hundred percent increase in breast cancer incidence over the expected
population rate.
53. See Incidence of Cancer, supra note 46, at 1833.
54. See Curtis C. Harris, P53: At the Crossroads of Molecular Carcinogenesis and Risk
Assessment, 262 SCIENCE 1980, 1981 (1993) (discussing the mutational spectra associated with
the tumor suppressor gene p53).
55. See David Malkin et al., Germ Line P53 Mutations in a Familial Syndrome of Breast
Cancer, Sarcomas, and Other Neoplasms, 250 SCIENCE 1233, 1237 (illustrating that alterations of
the p53 gene occur not only as somatic mutations in human cancers, but also as germline
mutations in some cancer-prone families).
56. See M. Starink et al., The Cowden Syndrome: A Clinical and Genetic Study in 21
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Table 1: Chromosomal Location and Cancer Risk for the
Common Breast Cancer Susceptibility Genes:
Family Cancer Cytogenetic
Syndrome jGene7  Location IF Selected Cancers
Hereditary Breast-Ovari- BRCA1* 17q21 early-onset breast, ovarian, pros-
an Syndromet tate, colon
Hereditary Breast-Ovari- BRCA2* 13q early-onset breast (both male and
an Syndrome" female breast), ovarian
Li-Fraumeni Syndrome p53" 17p13 breast, prostate, lung, colon,
(LFS)6 bladder, liver, brain, adrenal,
lymphomas/leukemia
Hereditary Non-Polypo- hMSH2* 2 colon, bladder, ovarian, breast
sis Colorectal Cancer
(HNPCC)"
Hereditary Non-Polypo- hMLHI* 3 p 2 l. 2 -2 3  colon, bladder, ovarian, breast
sis Colorectal Cancer
(HNPCC '2
Hereditary Non-Polypo- PMS1 2q31-33 colon, bladder, ovarian, breast
sis Colorectal Cancer
(HNPCC) 3 _____
Hereditary Non-Polypo- PMS2 7p22 colon, bladder, ovarian, breast
sis Colorectal Cancer
(HNCC)_
Ataxia Telangiectasia ATM 17q21 early-onset breast, ovarian, pros-
Heterozygote_ tate, colon
Cowden Syndrome not identi- 10q22 thyroid cancer, intestinal polypo-
fled sis, breast cancer
Patients, 29 CLINICAL GENErcs 222,222 (1986).
57. Gene names marked with an * are available for predictive genetic testing on a
commercial or research basis. (Copies of testing literature are on file with author).
58. See Csilla I. Szabo & Mary-Claire King, Inherited Breast and Ovarian Cancer, 4 HuM.
MOLECULAR GElErrcs 1811, 1811, 1813 (1995).
59. Id. at 1811.
60. See Harris, supra note 54, at 1981 (stating that germline p53 mutations are missense
and occur frequently in the cancer-prone individuals with Li-Fraumeni syndrome); Culotta &
Koshland, supra note 33, at 1958.
61. See John C. D'Emilia et al., The Clinical and Genetic Manifestations of Hereditary
Non-polyposis Colorectal Carcinoma, 169 AM. J. SURGERY 368, 368-70 (1995) (discussing the
clinical characteristics, pathology, genetics, management, and surveillance of hereditary non-
polyposis colorectal cancer). See generally Henry T. Lynch et al., Genetics, Natural History
Tumor Spectrum, and Pathology of Hereditary Non-polyposis Colorectal Cancer: An Updated
Review, 104 GASTROENTEROLOGY 1535 (1993) (summarizing current knowledge on hereditary
non-polyposis colorectal cancer (HNPCC) and the manner in which this knowledge can be
employed effectively for diagnosis and management of the disease).
62. See generally D'Emilia, supra note 61, at 369-70; Lynch et al., supra note 61.
63. See generally D'Emilia, supra note 61, at 371; Lynch et al., supra note 61.
64. Id.
65. See generally Mendelian Inheritance in Man, supra-note 50.
66. See Starink et al., supra note 56, at 225.
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Perhaps the most common inherited form of breast cancer
is hereditary breast-ovarian syndrome, or familial pre-
menopausal breast cancer. This is an autosomal dominant con-
dition where female family members can develop cancer of the
breast at a young age, often in the fourth decade, and have a
high incidence of bilateral breast cancer and ovarian cancer.67
This syndrome can also affect male members of the family
since men have an increased risk for prostate cancer and, in
some families, breast cancer as well. The evidence for an ele-
vated risk for breast cancer is primarily from epidemiologic
studies of families with multiple members with breast can-
cer.6" For these women, the lifetime risk for cancer can be as
high as eighty to one hundred percent.69
While longitudinal and genetic studies of high-risk fami-
lies suggested the hereditary nature of some breast cancers, it
was not until 1990 that researchers identified the chromosomal
location of BRCA1 on 17q21. 7 ° Four years later, the long
search culminated in the identification and cloning of the
BRCA1 gene.7' This discovery was quickly followed by the
67. See King, supra note 34, at 89; Biesecker et al., supra note 5, at 1970 (noting that more
than fifty percent of the breast cancers in studied individuals occur before age fifty).
68. See M.C. King & R.C. Elston, Genetic Epidemiology of Breast Cancer: A Comment on
Heterogeneity, 2 GENETIC EPIDEMIOLOGY 167, 168 (1985) (clarifying that segregation of analysis
estimates of susceptibility gene frequencies based only on high-risk families do not reflect the
gene frequencies in the population containing high-risk families); Mary-Claire King et al., Genetic
Epidemiology of Breast Cancer and Associated Cancers in High-Risk Families lI Linkage
Analysis, 71 J. NAT'L CANCER INST. 463, 463 (1983). See generally Thomas A. Sellers et al.,
Epidemiologic and Genetic Follow-up Study of 544 Minnesota Breast Cancer Families: Design
and Methods, 12 GENETIC EPIDEMIOLOGY 417 (1995) (concluding that the collection of detailed
information on epidemiologic risk factors will facilitate careful analysis of genetic and
environmental interaction, which will increase our understanding of how BRCAI, BRCA2, and
other genes influence risk).
69. See King et al., supra note 34, at 1978.
70. See Jeff M. Hall et al., Linkage of Early-Onset Familial Breast Cancer to Chromosome
17q21, 250 SCIENCE 1684, 1684 (1990).
71. See Elisabeth Steichen-Gersdorf et al., Familial Site-Specific Ovarian Cancer is Linked
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identification of a second major breast cancer susceptibility
gene called Breast Cancer 2 (BRCA2) on chromosome 1372
which was cloned a few months later.73 While the exact func-
tion of these genes is still unknown, mutations in BRCA1 and
BRCA2 predispose gene carriers to develop breast and other
cancers at an early age. The cumulative breast cancer risk for
putative BRCA1 carriers is extremely high, nearly fifty percent
by age fifty and eighty-five percent by age seventy.74 In addi-
tion, the risk for ovarian cancer is also greatly elevated to
about thirty to forty percent by age sixty, in contrast to the
average lifetime risk of 1.4% for American women." Molecu-
lar linkage studies have shown that approximately fifty to
eighty percent of breast cancers in high-risk families are caused
by BRCA1. 76
The BRCA1 gene is a large, novel gene of unknown func-
tion that extends over 100,000 bases of genomic DNA. 77 Nu-
merous mutations and polymorphisms78 have been identified
to BRCAI on ]7q-12-21, 55 AM. J. HUM. GENETics 875, 875 (1994) (establishing a linkage of
families with site-specific ovarian cancer to the breast-ovarian cancer susceptibility gene
(BRCAI) on chromosome arm 17q). See also Mild et al., supra note 33, at 66-67.
72. See Richard Wooster et al., Localization of a Breast Cancer Susceptibility Gene,
BRCA2, to Chromosome 13q12-13, 265 SCIENCE 2088,2088-89 (1994) [hereinafter Wooster et al.
1994] (noting the different phenotypes between BRCA1 and BRCA2 include a lower risk of
ovarian cancer attributable to BRCA2 and a higher risk of male breast cancer attributable to
BRCA2).
73. See Richard Wooster et al., Identification of the Breast Cancer Susceptibility Gene
BRCA2, 378 NATURE 789, 790 (1995) (identifying the BRCA2 gene as localized to chromosome
13q12-q13).
74. See Douglas F. Easton et al., Breast Ovarian Cancer Incidence in BRCAI Mutation
Carriers, 56 AM. J. HUM. GENETICS 265, 267 (1995) (estimating the age-specific risks of breast
and ovarian cancer in BRCA1 mutation carriers).
75. See Deborah Ford et al., Risks of Cancer in BRCAI-Mutation Carriers, 343 LANCET
692, 694 (1994) (providing estimates of breast and ovarian cancer risks that may be useful for
counseling BRCA1 mutation cancers).
76. See Simon A. Gayther et al., Germline Mutations of the BRCAI Gene in Breast and
Ovarian Cancer Families Provide Evidence for a Genotype-Phenotype Correlation, 11 NATURE
GENETICS 428,428 (reporting the identification of germline BRCAI mutations in 32 families with
a history of breast and/or ovarian cancer); Ford et al., supra note 75, at 692.
77. See Mild et al., supra note 33, at 67.
78. See THOMPSON ET AL., supra note 17, at 436, 438 (defining mutation and
polymorphism). Mutations and polymorphisms are identified by differences in the order of
nucleotide base pairs in a segment of the gene. A mutation is a sequence alteration that may in-
capacitate or severely alter the normal function of a gene. A polymorphism is a sequence
alteration that has no impact in the function of the gene. Mutations may have a severe effect on
genetic function and can cause human disease. Polymorphisms are benign changes in the genetic
code that have no discernible effect on the individual. Polymorphisms are frequently identified by
genetic researchers and must be differentiated from true mutations.
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in families previously linked to the BRCA1 region. This dem-
onstrates that alterations in the gene have profound effects on
breast cell growth.79 Early studies of breast tumors showed
that the BRCA1 region was frequently deleted in approximate-
ly twenty percent of breast tumors during the process of tumor-
igenesis thereby indicating that it may function as a tumor sup-
pressor gene."0 Tumor suppressor genes are essential for nor-
mal cell processes and act as negative regulators of cell
growth." In fact, BRCA1 gene expression has been shown to
be altered in breast epithelial cells in sporadic tumors.8 2 Mo-
lecular clues for BRCAI's specific role within the breast epi-
thelial cell are provided by recent studies that identified two
separate nucleotide base pair sequence motifs. 3 Analysis of
the BRCA1 sequence in the initial portion of the gene has
located a motif called a "ring finger" commonly found in genes
that function as transcription factors.84 The second sequence
motif is deep within the gene and is homologous to other se-
79. See Szabo & King, supra note 58, at 1815 (suggesting that BRCA1 may regulate
mammary epithelial growth and be somatically inactivated in breast cancer by a direct mutation or
by alterations in gene expression).
80. See S.A. Smith et al., Allele Losses in the Region 17q12-21 in Familial Breast and
Ovarian Cancer Involve the Wild-Type Chromosome, 2 NATURE GENETICS 128, 128 (1992)
(showing that allele losses in the tumors of affected family members also affect the wild-type
chromosome).
81. See Gary R. Skuse & Peter T. Rowley, Tumor Suppressor Genes and Inherited
Predisposition to Malignancy, 16 SEMINARS ONCOLOGY 128, 128, 133 (1989) (discussing the
roles of various tumor suppressor genes in tumorigenesis). See generally Christopher J. Marshall,
Tumor Suppressor Genes, 64 CELL 313, 313 (1991) (stating that multistage carcinogenesis
involves a cooperation between activated oncogenes and tumor suppressor genes).
82. See Sandra T. Marquis et al., The Developmental Pattern of BRCAl Expression Implies
a Role in Differentiation of the Breast and Other Tissues, 11 NATURE GENETICS 17, 17, 22, 24
(1995) (supporting that BRCA1 is involved in the process of proliferation and differentiation of
multiple tissues, notably in the mammary gland in response to ovarian hormones); Marilyn E.
Thompson et al., Decreased Expression of BRCA1 Accelerates Growth and is Often Present
During Sporadic Breast Cancer Progression, 9 NATURE GENETICS 444, 444, 448-49 (explaining
that decrease of activity of BRCAI measured by BRCA1 mRNA is associated with accelerated
growth of both normal and malignant mammary cells); Yumay Chen et al., Aberrant Subcellular
Localization of BRCAI in Breast Cancer, 270 SCIENCE 789, 791 (1995) (stating that the
subcellular mislocation of BRCAI protein suggests that abnormalities in BRCA1 are fundamental
to the genesis or progression of most breast cancers).
83. Genes are composed of deoxyribonucleic acid, or DNA. The molecular structure of
DNA is a linear array of four specific building blocks, or nucleotide bases. A basepair is formed
when a base specifically lines-up (pairs) with its partner on a complementary strand of DNA. The
two complementary strands form the DNA double helix. The specific sequence, or order, of the
basepairs form the genetic code. In addition, analysis of a gene segment can reveal functional
units of the gene called sequence motifs. THOMPSON ET AL., supra note 17, at 33.
84. See Miki et al., supra note 33, at 70.
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quence motifs, called granins, which may guide the movement
of proteins within the cell architecture, thereby suggesting that
BRCA1 may be secreted from the breast cell. 5
A second locus has been linked, in multiplex families with
early-onset breast cancer, to an area of chromosome 13.86 The
gene, BRCA2, is associated with pre-menopausal female and
male breast cancer, suggesting that BRCA1 and BRCA2 have
different biologic functions in the breast epithelial cell. The
gene was recently located on human chromosome 13 and early
studies have suggested that it accounts for a significant propor-
tion of pre-menopausal breast cancer.8 7 BRCA2 is a large
gene with numerous mutations and polymorphisms.8 Re-
searchers have suggested that the cancer risk for female breast
and ovarian cancer is also unusually high in both BRCA1 and
BRCA2; however, families with breast cancer linked to
BRCA2 are distinguished by a high incidence of male breast
cancer.
8 9
V. CLINICAL IMPLICATIONS OF GERMLINE
BRCA1 MUTATIONS
While predisposition testing is an emerging theme in mod-
em medicine, most experts agree that the medical community
should exercise caution when introducing new genetic tests into
patient care. Laboratory based molecular tests are relatively
new and BRCA1 mutations are particularly challenging be-
cause of the large number of mutations and polymorphisms in
the gene.9° Other issues have slowed the integration of
85. See Patricia S. Steeg, Granin Expectations in Breast Cancer?, 12 NATURE GENErICS
223,223-24 (1996) (proposing that BRCA1 performs the novel function of being a member of the
Granin family, a family of acidic proteins that bind calcium and aggregate in its presence).
86. See Wooster et al. 1994, supra note 72, at 2088-89. The BRCA2 gene is located on a
part of chromosome 13 which shows loss of heterozygosity in sporadic breast and ovarian
cancers. Id. at 2089. Although this suggests that BRCA2 is inactivated during oncogenesis, the
tumor suppressor gene RB 1 is also located in this region of chromosome 13 and may explain the
observed loss of heterozygosity. Id.
87. See Wooster et a]., supra note 73, at 789; Wooster et al. 1994, supra note 72, at 2088-
89.
88. See Susan Neuhausen et al., Recurrent BRCA2 6174delT Mutations in Ashkenazi-Jew-
ish Women Affected by Breast Cancer, 13 NATURE GENETCS 126, 126 (1996).
89. See Szabo & King, supra note 58, at 1811. Stephen H. Friend, Breast Cancer
Susceptibility Testing: Realities in the Post-Genomic Era, 13 NATURE GENETICS 16, 16 (1996)
(summarizing studies which link BRCA2 alterations to increased cancer risks).
90. See Miki et al., supra note 33, at 71; Struewing et al., supra note 1, at 198; Lori S.
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BRCA1 testing into clinical practice,9' such as proper inter-
pretation of the test, appropriate medical management and
cancer screening recommendations, as well as adequately
trained health professionals to perform testing.92 A better un-
derstanding of the mechanisms of the genes that cause suscep-
tibility for breast cancer, as well as the potential interaction
between genes are essential, yet unanswered, questions.
The attributable risk, or proportion of breast cancers in the
general population due to BRCA1 mutations, is a very impor-
tant issue in cancer susceptibility testing. Mutations in the gene
may be relatively common in the population, approximately
1/500 to 1/1000, but gene frequency estimates have primarily
been based on information collected from high-risk families.93
Early reports suggested that there is a low proportion of
BRCA1 mutations in women who have sporadic breast cancer
unselected for a strong family history.94 However, one recent
study from the National Cancer Institute and the National Cen-
ter for Human Genome Research identified a specific mutation,
185delAG, 95 in 0.9% of Ashkenazi-Jewish individuals.96 This
Friedman et a]., Confirmation at BRCAI by Analysis of Germline Mutations Linked to Breast and
Ovarian Cancer in Ten Families, 8 NATURE GENETICS 399, 400 (1994) (confirming that the
BRCA1 gene is responsible for inherited predisposition to breast and ovarian cancers in some
families); Steven A. Narod et al., An Evaluation of Genetic Heterogeneity in 145 Breast-Ovarian
Cancer Families, 56 AM. J. HUM. GENErIcs 254, 254 (1995) (finding evidence for heterogeneity
of the breast-ovarian cancer syndrome). See generally Shattuck-Eidens, supra note 2.
91. See Garber & Schrag, supra note 6, at 1928-29 (discussing the current transition period
for inherited cancer predisposition in which the health care professional is forced to integrate the
rapidly evolving technology and expanding knowledge base of cancer genetics into patient care
paradigms).
92. See American Society of Clinical Oncology, supra note 4, at 1731-35.
93. See D. Ford et al., Estimates of the Gene Frequency ofBRCAI and Its Contribution to
Breast and Ovarian Cancer Incidence, 57 AM. J. HUM. GENETICS 1457, 1459-60 (1995)
(providing evidence that the frequency of BRCA1 mutation cariers in the general population is
low); Skolnick & Cannon-Albright, supra note 30, at 1749-50 (noting that traditionally, studies
have focused on families with breast cancer and although this approach is a poor method for
determining the mode of inheritance, it has been useful in collecting families for linkage studies);
Claus et al., supra note 42, at 232, 241.
94. See Andrew Futreal et al., BRCA1 Mutations in Primary Breast and Ovarian Carci-
nomas, 266 SCIENCE 120, 120, 122 (1994) (concluding that BRCAI has a role in early-onset
breast and ovarian cancer, but may only have a minor role in sporadic breast and ovarian tumor
formation).
95. This designation indicates that the mutation occurs at codon 185 of the BRCAI gene
(185), the mutation is a deletion, or loss, of genetic material (del), and that the two deleted bases
are an adenosine (or A) and a guanine (or G) nucleotides.
96. See Struewing et al., supra note 1, at 199 (noting that the observed .9% prevalence of
the 185delAG mutation is higher than the prevalence of many genetic diseases for which routine
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study was performed on DNA previously collected, in a sepa-
rate research protocol, from 858 blood samples from donors of
Ashkenazi-Jewish descent, 7 and 815 donors of a mixed ethnic
background. Using a molecular protocol that only tested for the
185delAG mutation in exon 2 of the BRCA1 gene, eight of the
Ashkenazi-Jewish group and none of the mixed ethnic group
had an abnormal BRCA1 test. Other researchers noticed a
higher prevalence of the 185delAG mutation in Ashkenazi-
Jewish breast cancer families,98 but this was the first study
that directly examined presumably healthy individuals from a
specific ethnic background.
Calling this proportion of germline BRCA1 carriers an
"unexpectedly high frequency," the authors proposed simplified
genetic screening for a specific ethnic group. However, the
authors," and others"°  acknowledge that longitudinal studies
are required to clarify the cancer risk for individuals who are
tested without knowledge of their family history. This finding
has highlighted the profound uncertainties of molecular genetic
testing for cancer susceptibility.
The central issue for the health care provider is determin-
ing the attributable risk for cancer from a specific cancer sus-
ceptibility gene. One approach that has been used to determine
risk for breast cancer is to estimate the proportion of breast
cancers that are associated with germline BRCA1 mutations as
a function of age at cancer diagnosis. Using prevalence figures
and age-dependent incidence figures for the observed risk of
breast cancer in families with BRCA1, D. Ford, et al. calculat-
screening is conducted).
97. Id. at 198. These samples were previously collected in an unrelated study of families
with Tay-Sachs disease and were not selected for family history of cancer. Id.
98. See Patricia Tonin et al., BRCAI Mutations in Ashkenazi-Jewish Women, 57 AM. J.
HUM. GENETIcS 189, 189 (1995) (noting that six of the seven Ashkenazi families in the study
were found to carry the 185delAG mutation); David E. Goldgar & Philip R. Reilly, A Common
BRCA1 Mutation in the Ashkenazim, 11 NATuRE GENETCS 113, 113 (1995); Szabo & King,
supra note 58, at 1813-14 (noting that the 185delAG mutation illustrates a "striking example" of
the founder effect among BRCAI mutations).
99. See Struewing et al., supra note I, at 199 (noting however that further research will be
required to determine whether screening reduces morbidity and mortality from these diseases).
100. See Collins, supra note 2, at 187 (stating that the value of a negative test is minimal
unless an affected relative is known to carry a particular BRCA1 mutation that can be shown to be
absent in the person at risk); Gerber & Schrag, supra note 6, at 1929 (stating that physicians
should encourage their patients to participate in research studies).
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ed that 7.5% of women less than thirty years of age from
mixed ethnic groups, are expected to have a germline BRCA1
mutation.'
Genetic analysis of blood samples from young breast can-
cer cases has confirmed these estimates. Two papers recently
published in the New England Journal of Medicine directly
tested the frequency of BRCA1 mutations in young women
with breast cancer. Using a DNA sequencing approach that is
estimated to identify approximately ninety percent of known
mutations, Amelia A. Langston, et al. studied eighty women
from a larger population based cohort who were less than thirty
years of age at diagnosis. About ten percent of this selected
group had BRCA1 germline defects0 2 which is in accordance
with previous epidemiologic estimates. Limited family history
information was known, but none of the cases were members
of large, high-risk breast cancer families.
The proportion of young Ashkenazi-Jewish women with
breast cancer was reported in Michael 01 FitzGerald, et al.'s
accompanying article. 3 Using a combination of automated
DNA sequencing and protein-truncation assays,' this study
examined the germline BRCA1 status of 418 women of mixed
ethnicity with breast cancer including thirty-nine Jewish wom-
en under age forty. Eight (twenty-one percent) of the young
Ashkenazi-Jewish women had a germline 185delAG mutation
of the BRCA1 gene. The study also found that a minority (thir-
teen percent of thirty) of women of mixed ethnicity under the
age of thirty also had identifiable BRCA1 mutations. While the
two study populations are not directly comparable, both groups
of researchers demonstrated that a significant proportion of
young Ashkenazi-Jewish woman with breast cancer carried the
101. See D. Ford et al., Estimates of the Gene Frequency of BRCAI and its Contribution of
Breast and Ovarian Cancer Incidence, 57 AM. J. HUM. GENETICS 1457, 1457-62 (1995).
102. See Amelia A. Langston et al., BRCAI Mutations in a Population-Based Sample of
Young Women with Breast Cancer, 334 NEW ENG. J. MED. 137, 137, 141 (1996).
103. Michael G. FitzGerald eta]., Germ-Line BRCA) Mutations in Jewish and Non-Jewish
Women with Early-Onset Breast Cancer, 334 NEw ENG. J. MED. 143, 144 (1996) (finding a one
percent prevalence of the BRCAI mutation in Ashkenazi-Jewish women).
104. Id. at 144-45. Genetic analysis is performed using a wide variety of molecular
techniques. DNA sequencing involves chemically determining the order of nucleotide bases in a
segment of DNA and can be performed using automated machinery. The protein-truncation assay
specifically identifies mutations that prevent the synthesis of a functional protein from a gene. Id.
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185delAG mutation. These investigators also illustrated that
BRCA1 mutations are not limited to women with a strong
family history of breast cancer.
The multiplicity of genes that may cause breast cancer has
contributed to the difficulties of BRCA1 predictive testing.
Recent studies have shown that there is a specific mutation,
6174delT, in the BRCA2 breast cancer susceptibility gene in a
significant proportion of Ashkenazi women who have devel-
oped early-onset breast cancer." However, as suggested by
S.V. Tavtigian, et al. the 6174delT (BRCA2) and 185delAG
(BRCAl) mutations may account for a significant proportion of
breast cancer in the Ashkenazi-Jewish population." The in-
crease in specific mutations in BRCA1 and BRCA2 is a reflec-
tion of a founder effect"7 and has been noted in other ethnic
populations."'
In a recent New England Journal of Medicine editorial,
Dr. Francis Collins, the Director of the National Center for
Human Genome Research, noted that there is growing interest
in BRCA1 genetic testing within the Ashkenazi-Jewish com-
munity. He also announced a larger study of the 185delAG
mutation in approximately five thousand Ashkenazi-Jewish
individuals who were unselected for cancer or a family history
of cancer."° By using this method, the prevalence of the ge-
netic mutation can be correlated to the clinical histories of the
study participants. Therefore, the attributable risk of this muta-
105. See S.V. Tavtigian et al., The Complete BRCA2 Gene and Mutations in Chromosome
13q-LinkedKindreds, 12 NATURE GENEICS 333, 335 (1996) (discussing a mutational analysis of
the BRCA2 gene with mutations mapped to chromosome 13q); Neuhausen et al., supra note 88, at
127 (stating that the frequency of the 6174delT mutation in Ashkenazi women can be estimated to
be 3 per 1,000; however, if the penetrance of this mutation is lower than BRCA1, then the
frequency of this mutation will be higher).
106. Tavtigian et al., supra note 105, at 335.
107. A founder effect is defined as "high frequency of a mutant gene in a population
founded by a small ancestral group when one or more of the founders was a carrier of the mutant
gene." THOMPSON ET AL., supra note 17, at 432.
108. See Steinunn Thorlacius et al., A Single BRCA2 Mutation in Male and Female Breast
Cancer Families from Iceland With Varied Cancer Phenotypes, 13 NATURE GENETICS 117, 117-
18 (studying BRCA2 in twenty-one Icelandic families); Friend, supra note 89, at 16 (discussing
mutations in the BRCA2 gene in Icelandic families); Szabo & King, supra note 58, at 1811-17.
109. See Collins, supra note 2, at 187 (stating that more definitive answers as to whether it is
unlikely that the risk of early-onset breast cancer in women with BRCA1 mutations will be
markedly lower than that observed in previously well-studied families, will be provided by the
announced study).
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tion can be better understood.
Dr. Collins called for restraint in pursuing genetic testing
in an unregulated environment and concluded that genetic test-
ing should continue to be performed on a research basis where
full informed consent and genetic counseling can be provided
to the patient."0 Other groups have closely examined these
issues and have published recommendations for cancer suscep-
tibility testing."' For example, the American Society of Hu-
man Genetics published a series of recommendations soon after
the BRCA1 gene was identified in 1994. These recommenda-
tions encouraged the establishment of protocols to research the
clinical models for genetic testing. The American Society of
Human Genetics stated that "it is premature to offer population
screening until the risk associated with specific BRCA1 muta-
tions are determined and the best strategies for monitoring and
prevention are accurately assessed.""' Likewise, the National
Advisory Council for Human Genome Research urged that "it
is premature to offer testing of either high-risk families or the
general population as part of general medical practice until a
series of crucial questions has been addressed."' ' 3
The American Society of Clinical Oncology (ASCO) pub-
lished recommendations for clinical oncologists in February,
1996." 4 In particular, ASCO stated that "to the greatest ex-
tent possible, genetic testing for cancer susceptibility should be
performed in the setting of long-term outcome studies." These
types of outcome studies are necessary to understand the prob-
able risk of cancer for a given gene mutation."5 Additionally,
these studies are essential to explore the issues surrounding a
patient's desire to know their genetic diagnosis when coupled
110. See Collins, supra note 2, at 188 (stating that the possible clinical application of
BRCA1 testing presents an interesting dilemma: on the one hand the uncertain risks and benefits
require that testing be conducted only under strict protocol; on the other hand, interest in such
studies is growing, but such studies can accept only a limited number of women).
111. See generally National Advisory Council, supra note 4; American Society of Clinical
Oncology, supra note 4. See also ASHG, supra note 4.
112. Id.
113. National Advisory Council, supra note 4.
114. See American Society of Clinical Oncology, supra note 4, at 1730.
115. See Arthur Schatzkin et al., What Does it Mean to be a Cancer Gene Carrier?
Problems in Establishing Causality From the Molecular Genetics of Cancer, 87 J. NAT'L CANCER
INST. 1126, 1130 (1995) (concluding that further epidemiological studies must be conducted
before results from studies of cancer-prone families can be applied to the general population).
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with potential employment and insurance discrimination. 16
Although these issues are more fully discussed in this
issue of Health Matrix,"7 the ramifications of patient decision
making is provided by Caryn Lerman, et al."8 This study in-
vestigated the attitudes and concerns of 279 male and female
members of families that were previously linked to the BRCA1
gene as they progressed through predictive testing for BRCA1
germline mutations. One surprising result was that only forty-
three percent"9 of study's subjects requested their BRCA1
mutation results. This was striking when contrasted to the
author's previous research that suggested that ninety-one per-
cent of family members in high-risk families would want test-
ing for BRCA1 mutations. 2  This study also showed that
there was significant concern about potential loss of health
insurance.'
116. See Katherine A. Schneider et al., Testing for Cancer Genes: Decisions, Decisions, 1
NATuRE MED. 302, 302-03 (1995) (stating that health care providers should not assume that all
individuals at risk for hereditary cancer predisposition on the basis of family history will be
interested in testing at the moment it is offered); Nancy J. Nelson, Caution Guides Genetic Testing
for Hereditary Cancer Genes, 88 J. NAT'L CANCER INsT. 70, 71-72 (1996) (discussing the role
psychological factors and insurance concerns have on an individual's decision to be tested); Kathy
L. Hudson et al., Genetic Discrimination and Health Insurance: An Urgent Need for Reform, 270
SCIENCE 391, 391-92 (1995) (arguing that genetic-based exclusion of high-risk candidates from
insurance coverage will make individuals less likely to participate in genetic research and to share
genetic information with health care providers or family members); Biesecker et al., supra note 5,
at 1973 (stating that it is not advantageous for women who have BRCA1 to have their insurance
companies learn the results of their screening; however, if an insurance company emphasizes
preventive care, it may be willing to reimburse for preventive medical intervention such as
screening).
117. See generally 7 HEALTH MATRIX 1 (compiling articles from the April 1996 Symposium
regarding the social, ethical, religious, scientific, and legal implications of genetic testing for the
BRCA1 gene).
118. See generally Caryn Lerman et al., BRCA1 Testing in Families with Hereditary Breast-
Ovarian Cancer: A Prospective Study of Patient Decision Making and Outcomes, 275 JAMA
1885 (1996) (identifying predictors of utilization of breast-ovarian cancer susceptibility BRCA1
gene testing) [hereinafter BRCAI Testing in Families].
119. Id. at 1888. The author states that the primary goals of the study were: "(1) to examine
predictors of decisions to receive BRCA1 test results, including sociodemographic factors,
knowledge, and preceptors of the benefits, limitations, and risks of testing; (2) to evaluate the
effects of BRCA1 testing on psychological and functional health status; and (3) to evaluate how
testing influences participant's medical decisions." Id. at 1886.
120. See Caryn Lerman et al., Interest in Genetic Testing Among First-Degree Relatives of
Breast Cancer Patients, 57 AM. J. MED. GENErIcs 385, 387 (1995) (stating that the most
commonly cited reasons for being tested were the following: to learn about one's childrens' risks;
to increase the use of cancer screening tests; and, to take better care of oneself).
121. BRCAI Testing in Families, supra note 118, at 1891 (suggesting that the concern stems
from possible discrimination in enrollment, discontinuation of insurance, or increased premium
rates).
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The issues and concerns presented by Caryn Lerman, et al.
parallel the reactions of the two Center for Human Genetics
patients presented earlier. Both of these Ashkenazi women
were deeply concerned about their own health, but also feared
the effect the test might have on the well-being of their fami-
lies and the larger community. How we address their concerns
for BRCA1 testing will be debated and studied on a national
level. However, it is imperative that molecular analysis for
BRCA1 and other cancer predisposition genes be performed
within the context of scientific protocols in order to determine
the predictive value of such testing. Only through a combined
approach of genetic, medical, ethical, and legal research can
we truly determine whether the risks for genetic testing are too
great, or the benefits too small for the entire community.
